BioXcel Therapeutics Inc (FRA:BX2)
€ 1.892 0.006 (0.32%) Market Cap: 72.49 Mil Enterprise Value: 98.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

BioXcel Therapeutics Inc To Discuss The Data Results From The Phase 2 Trial of BXCL701 Call Transcript

Oct 10, 2023 / 12:00PM GMT
Release Date Price: €3.09 (+20.53%)
Operator

Good morning, and welcome to the BioXcel Therapeutics conference call to review the positive overall survival results from the company's Phase II trial of BXCL701 for patients with small cell neuroendocrine prostate cancer. (Operator Instructions)

Just to remind everyone, certain matters discussed in today's conference call and/or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and/or the future financial or business performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements. Risk factors that may affect future results are detailed in the company's quarterly report on Form 10-Q for the quarterly period ended June 30, 2023, which can be found at www.bioxceltherapeutics.com or on www.sec.gov. As a reminder, today's conference call and webcast are being recorded.

Joining us are Dr. Vimal Mehta,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot